Bone Diseases, Infectious
8
3
3
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Fosfomycin I.v. for Treatment of Severely Infected Patients
Gene Expression Profiles in Spinal Tuberculosis.
Clindamycin-rifampin Drug Interaction in the Treatment of Bone and Joint Infections
Spinal Infection Management With Structural Allograft
Pressure Ulcer-associated Osteomyelitis: Evaluation of a Two-stage Surgical Strategy With Prolonged Antimicrobial Therapy
Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery
Retrospective Study of Bone Infection Due to Campylobacter Spp